Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab
Patients receiving eculizumab have an increased risk for meningococcal disease, but most reported cases are attributable to encapsulated meningococcal strains. We describe a case in which a nongroupable meningococcal strain, which rarely causes disease in healthy persons, caused fatal disease in an...
Main Authors: | Deirdre Nolfi-Donegan, Monica Konar, Vianca Vianzon, Jessica MacNeil, James Cooper, Perrianne Lurie, Judi Sedivy, Xin Wang, Dan M. Granoff, Lucy McNamara |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2018-08-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/24/8/18-0228_article |
Similar Items
-
Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland
by: Robert M. Mulhall, et al.
Published: (2018-08-01) -
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology
by: Vega Masignani, et al.
Published: (2019-04-01) -
Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced
by: S K Sethi, et al.
Published: (2017-01-01) -
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
by: Al-Ani F, et al.
Published: (2016-08-01) -
Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
by: Michael J. Fassett, et al.
Published: (2021-04-01)